Dermatology Times, February 2022 (Vol. 43. No. 2)

Clinical trials investigate biologics, JAK inhibitors, and additional systemic treatments as first-line alternatives to or adjuvant therapies alongside surgery.

Unsafe and toxic skin-whitening products continue to draw fire.

A dermatologist needs to know how to treat every patient, regardless of skin or hair type. These pointers will help guide conversations with patients for the best possible hair care.

Slathering the body with the same skin-care products designed for the face is a bad idea, experts say.

Experts outline strategies for patient conversations around the black box warning.

Acne may be the most common skin condition in the United States, with various studies estimating that 79% to 95% of Americans aged 12 to 24 year’s experience at least a minor case, yet diagnosing, treating, and managing care for pediatric patients affected by acne has never been more complex.

Both legal and tax factors come into play when deciding on the best corporate structure for a dermatology practice.

In this month's Cosmetic Conundrum, Zoe Diana Draelos, MD, dives into common cleanser questions, a topic she also discussed at the Science of Skincare Summit, New York, New York, on November 6, 2021.

In this month's Legal Eagle, we dive into a case of a potential OSHA violation at a practice.

Defining the goals of the mentoring relationship can be useful to clarify expectations.

Treatments awaiting FDA approval could bolster the range of nonsteroids and well-tolerated topicals aimed at combating pediatric cutaneous disorders.

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Neal Bhatia, MD, highlights new approaches in rosacea therapy in his session at the Fall Clinical Dermatology Conference for PAs & NPs.